We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Genedrive plc (GDR) Ordinary 1.5p Shares

Sell:2.15p Buy:2.30p 0 Change: 0.15p (6.32%)
Market closed Prices as at close on 8 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:2.15p
Buy:2.30p
Change: 0.15p (6.32%)
Market closed Prices as at close on 8 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:2.15p
Buy:2.30p
Change: 0.15p (6.32%)
Market closed Prices as at close on 8 November 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

genedrive plc is a United Kingdom-based pharmacogenetic testing company. The Company is engaged in developing and commercializing a rapid, versatile, simple to use and robust point-of-need pharmacogenetic platform for the diagnosis of genetic variations. The Company’s products include Genedrive MT-RNR1 ID Kit, Genedrive System, and Genedrive CYP2C19 ID Kit. The Company’s flagship product Genedrive MT-RNR1 ID Kit is a single-use disposable cartridge that circumvents the requirement for cold chain logistics by providing temperature stable reagent test kits for use on their proprietary test platform. The Genedrive System is a rapid thermocycler and signal detection system, enabling PCR and isothermal based amplification techniques. It is a semi- automated system used for qualitative in vitro molecular diagnostic tests. Its Genedrive CYP2C19 ID Kit Molecular point-of-care test for rapid CYP2C19 genotyping in time-critical emergency care settings.

Contact details

Address:
48 Grafton Street
MANCHESTER
M13 9XX
United Kingdom
Telephone:
+44 (0161) 9890245
Website:
www.genedriveplc.com/

Important dates

Future events
There are no future events available.
Past events
General meeting 31 May 2024 31/05/24
Interim results 28 March 2024 28/03/24
AGM 29 December 2023 29/12/23
Annual report 06 December 2023 06/12/23
Final results 30 November 2023 30/11/23
AGM 30 November 2023 30/11/23

General stock information

EPIC:
GDR
ISIN:
GB00B1VKB244
Market cap:
£12.08 million
Shares in issue:
543.14 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Gino Miele
    Chief Executive Officer, Executive Director
  • Russell Shaw
    Chief Financial Officer, Executive Director, Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.